| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $86.1M | +68.7% |
| SG&A Expense | $37.4M | +100.1% |
| Operating Income | -$123.5M | -77.1% |
| Net Income | -$120.7M | -58.9% |
| EPS (Basic) | -$3.65 | +59.2% |
| EPS (Diluted) | -$3.65 | +59.2% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $179.3M | -34.7% |
| Current Assets | $186.6M | -33.0% |
| Total Assets | $211.4M | -24.5% |
| Current Liabilities | $31.6M | +69.1% |
| Total Liabilities | $50.6M | +170.2% |
| Stockholders' Equity | $160.8M | -38.5% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$89.3M | -152.9% |
| Capital Expenditures | $6.4M | +1085.0% |
| Investing Cash Flow | -$6.4M | -984.6% |
| Financing Cash Flow | $183K | -99.9% |
| Free Cash Flow | -$95.7M | -166.9% |